At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Lifitegrast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
In Brief
A Phase 2 clinical trial evaluating Lifitegrast and Placebo for Allergic Conjunctivitis. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartApr 2009
Primary CompletionMay 2009
TodayJul 2026
First PostedApr 16, 2009
Enrollment StartApr 24, 2009
Primary CompletionMay 10, 2009
TodayJul 2, 2026
Enrollment to primary: 16 daysPosted 17.2 years ago
Interventions
Lifitegrastdrug
Ophthalmic Solution
Placeboother
Ophthalmic Solution